ATAI vs SGE.L
ATAI: Atai Beckley is a clinical-stage biotech firm developing novel treatments for central nervous system disorders. SGE.L: Sage provides cloud-native financial, HR, and payroll software solutions tailored to the needs of small and medium-sized enterprises globally.
Side-by-side fundamentals
| Metric | ATAI | SGE.L | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $7.38 | £10.86 | |
| Market cap as of 2026-08-25 | $2.7B | $13.3B | |
| Net margin as of 2026-08-25 | -19019.4% | n/a | |
| Operating margin as of 2026-08-25 | -18569.1% | n/a | |
| ROE as of 2026-08-25 | -366.5% | n/a | |
| ROA as of 2026-08-25 | -269.0% | n/a | |
| Debt / equity as of 2026-08-25 | 0.00 | n/a | |
| Revenue growth (YoY) as of 2026-08-25 | +86.7% | n/a | |
| Beta as of 2026-08-25 | 1.59 | n/a | |
| 1-year return as of 2026-08-24 close | +61.5% | -2.5% | ATAI higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.